Immunological effects of everolimus in patients with metastatic renal cell cancer

por Huijts, Charlotte M, Santegoets, Saskia J, de Jong, Tamarah D, Verheul, Henk M, de Gruijl, Tanja D, van der Vliet, Hans J
Publicado 2017

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer

por Labots, Mariette, Gotink, Kristy J, Dekker, Henk, Azijli, Kaamar, van der Mijn, Johannes C, Huijts, Charlotte M, Piersma, Sander R, Jiménez, Connie R, Verheul, Henk M W
Publicado 2016

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

por Huijts, Charlotte M, Santegoets, Saskia J, van den Eertwegh, Alfons J, Pijpers, Laura S, Haanen, John B, de Gruijl, Tanja D, Verheul, Henk M, van der Vliet, Hans J
Publicado 2011

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial

por Huijts, Charlotte M., Lougheed, Sinéad M., Bodalal, Zuhir, van Herpen, Carla M., Hamberg, Paul, Tascilar, Metin, Haanen, John B., Verheul, Henk M., de Gruijl, Tanja D., van der Vliet, Hans J.
Publicado 2019

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

por Huijts, Charlotte M., Werter, Inge M., Lougheed, Sinéad M., Goedegebuure, Ruben S., van Herpen, Carla M., Hamberg, Paul, Tascilar, Metin, Haanen, John B., Verheul, Henk M., de Gruijl, Tanja D., van der Vliet, Hans J.
Publicado 2018